ATE526988T1 - Methylphenidat-lösung und relevante verabreichungs- und herstellungsverfahren - Google Patents

Methylphenidat-lösung und relevante verabreichungs- und herstellungsverfahren

Info

Publication number
ATE526988T1
ATE526988T1 AT04785397T AT04785397T ATE526988T1 AT E526988 T1 ATE526988 T1 AT E526988T1 AT 04785397 T AT04785397 T AT 04785397T AT 04785397 T AT04785397 T AT 04785397T AT E526988 T1 ATE526988 T1 AT E526988T1
Authority
AT
Austria
Prior art keywords
methylphenidate
manufacturing methods
methylphenidate solution
solution
relevant administration
Prior art date
Application number
AT04785397T
Other languages
English (en)
Inventor
Clifford Herman
Original Assignee
Mallinckrodt Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mallinckrodt Llc filed Critical Mallinckrodt Llc
Application granted granted Critical
Publication of ATE526988T1 publication Critical patent/ATE526988T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4458Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT04785397T 2003-10-08 2004-10-07 Methylphenidat-lösung und relevante verabreichungs- und herstellungsverfahren ATE526988T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50970403P 2003-10-08 2003-10-08
PCT/US2004/033268 WO2005035000A1 (en) 2003-10-08 2004-10-07 Methylphenidate solution and associated methods of administration and production

Publications (1)

Publication Number Publication Date
ATE526988T1 true ATE526988T1 (de) 2011-10-15

Family

ID=34435016

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04785397T ATE526988T1 (de) 2003-10-08 2004-10-07 Methylphenidat-lösung und relevante verabreichungs- und herstellungsverfahren

Country Status (10)

Country Link
US (1) US7691880B2 (de)
EP (1) EP1680144B1 (de)
JP (1) JP4959335B2 (de)
CN (1) CN1867359B (de)
AT (1) ATE526988T1 (de)
AU (1) AU2004280240B2 (de)
CA (1) CA2540052C (de)
ES (1) ES2373042T3 (de)
MX (1) MXPA06003725A (de)
WO (1) WO2005035000A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE482695T1 (de) 2002-12-13 2010-10-15 Durect Corp Orale darreichungsform mit flüssigen hochviskosen trägersystemen
CA2645855C (en) 2006-03-16 2015-02-03 Tris Pharma, Inc. Modified release formulations containing drug-ion exchange resin complexes
EP2219622A1 (de) 2007-12-06 2010-08-25 Durect Corporation Verfahren zur behandlung von schmerzen, arthritischen zuständen oder entzündung im zusammenhang mit einer chronischen erkrankung
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
US8287903B2 (en) 2011-02-15 2012-10-16 Tris Pharma Inc Orally effective methylphenidate extended release powder and aqueous suspension product
CA2880456A1 (en) 2012-08-15 2014-02-20 Tris Pharma, Inc. Methylphenidate extended release chewable tablet
TW201521769A (zh) 2013-03-15 2015-06-16 Durect Corp 具有流變改質劑以減少溶解變異性之組成物
US11590228B1 (en) 2015-09-08 2023-02-28 Tris Pharma, Inc Extended release amphetamine compositions
SG11201811760VA (en) 2016-07-06 2019-01-30 Durect Corp Oral dosage form with drug composition, barrier layer and drug layer
CN106511264A (zh) * 2016-11-15 2017-03-22 北京万全德众医药生物技术有限公司 一种盐酸哌甲酯口服溶液剂及其制备方法
US12458592B1 (en) 2017-09-24 2025-11-04 Tris Pharma, Inc. Extended release amphetamine tablets
US11590081B1 (en) 2017-09-24 2023-02-28 Tris Pharma, Inc Extended release amphetamine tablets
EP4649943A1 (de) * 2024-05-17 2025-11-19 Medice Arzneimittel Pütter GmbH & Co. KG Reduzierte nitrosaminbildung in pharmazeutischen zusammensetzungen mit methylphenidat

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5354885A (en) * 1992-12-24 1994-10-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Process for preparing ethyl ester of L-DOPA
US6486177B2 (en) 1995-12-04 2002-11-26 Celgene Corporation Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
ATE277594T1 (de) 1998-06-03 2004-10-15 Alza Corp Vorrichtungen um eine verlängerte medikamententherapie zu erreichen
JP2000072674A (ja) * 1998-08-28 2000-03-07 Ota Seiyaku Kk ノスカピン経口医薬液剤
US6419960B1 (en) * 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
JP2000247883A (ja) * 1999-02-23 2000-09-12 Fujisawa Pharmaceut Co Ltd ジヒドロピリジン系化合物を含有する内服用液剤
US6127385A (en) * 1999-03-04 2000-10-03 Pharmaquest Limited Method of treating depression using l-threo-methylphenidate
WO2000074685A1 (fr) * 1999-06-02 2000-12-14 Sumitomo Pharmaceuticals Co., Ltd. Preparations orales d'etidronate disodique
JP2001106629A (ja) * 1999-10-04 2001-04-17 Material Eng Tech Lab Inc タンパク分解酵素阻害剤
IL136430A0 (en) * 2000-05-29 2001-06-14 Zviaguina Natalia Ray tracing method and system for determining visible parts of surfaces of three-dimensional objects and their parameters of shading accounting for light and shadow volumes
EP1163907B1 (de) 2000-06-17 2006-04-12 Pharmaquest Limited Verwendung von l-threo-methylphenidate zur Herstellung eines Medikaments für die Behandlung von Depression
EP1315495A2 (de) * 2000-08-28 2003-06-04 Sention, Inc. Verwendung von threo-methylphenidate-verbindungen zur erhöhung des erinnerungsvermögens
US20020132793A1 (en) 2000-08-28 2002-09-19 Mel Epstein Use of methylphenidate compounds to enhance memory
TWI277414B (en) * 2001-01-12 2007-04-01 Baxter Int Esmolol formulation
MY129350A (en) * 2001-04-25 2007-03-30 Bristol Myers Squibb Co Aripiprazole oral solution
DE60213592T2 (de) * 2001-05-25 2007-08-09 Warner-Lambert Co. Llc Flüssige pharmazeutische zusammensetzung
PE20030545A1 (es) * 2001-10-31 2003-06-19 Schering Corp Formulaciones de jarabe de ribavirina
US6962908B2 (en) * 2001-12-21 2005-11-08 Warner Chilcott Company Inc. Oral pharmaceutical products containing 17 β-estradiol-3-lower alkanoate, method of administering the same and process of preparation

Also Published As

Publication number Publication date
US7691880B2 (en) 2010-04-06
JP4959335B2 (ja) 2012-06-20
ES2373042T3 (es) 2012-01-30
CA2540052A1 (en) 2005-04-21
MXPA06003725A (es) 2006-06-23
EP1680144B1 (de) 2011-10-05
US20060205776A1 (en) 2006-09-14
AU2004280240A1 (en) 2005-04-21
CN1867359A (zh) 2006-11-22
AU2004280240B2 (en) 2010-04-22
JP2007508313A (ja) 2007-04-05
CN1867359B (zh) 2010-12-15
WO2005035000A1 (en) 2005-04-21
CA2540052C (en) 2012-04-10
EP1680144A1 (de) 2006-07-19

Similar Documents

Publication Publication Date Title
ATE526988T1 (de) Methylphenidat-lösung und relevante verabreichungs- und herstellungsverfahren
CY1116885T1 (el) Υποκατεστημενα παραγωγα κυκλοεξυλομεθυλιου
TW200626558A (en) Indazolone derivatives
MY146623A (en) Substituted prolinamides, manufacturing, and the use thereof as medicaments
WO2005009975A3 (en) Benzimidazole derivatives as mek inhibitors
WO2007015017A3 (fr) Nouveaux derives de polyquinoleines et leur utilisation therapeutique
CY1107846T1 (el) Παραγωγα κιναζολινονης χρησιμα ως βανιλλοειδεις ανταγωνιστες
WO2007061828A3 (en) Pharmaceutical compositions comprising buprenorphine
WO2005103037A3 (de) Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel
WO2006114401A3 (en) Novel cyclic amines
WO2011076209A3 (en) Pharmaceutical composition comprising solvent mixture and a vitamin d derivative or analogue
WO2009138847A3 (en) An improved process for the preparation of cefozopran
TW200517339A (en) Methods of purifying hydrogen fluoride
NO20080812L (no) Fremgangsmate for fremstilling av 4 β-amino-4'demetyl-4-4-desoksy podofyllotoksin
ECSP055844A (es) Nuevos compuestos triciclicos
TW200633963A (en) Novel cyclohexane derivatives
TW200626527A (en) Novel hexafluoroisopropanol derivatives
PA8581701A1 (es) Derivados de indolilo
WO2008135525A3 (en) Substituted azetidines, manufacturing and use thereof as medicaments
ATE373029T1 (de) Monomerenarme, niedrigviskose lösungen von tdi- isocyanuraten in verzweigten dialkylphthalaten
NO20053089D0 (no) Carbamidsyreestere med anticolinergisk virkning.
CY2011018I1 (el) Νεα κρυσταλλικη μορφη toy 8-kyan-1-kykλoπpoπyλ-7-(1s,6s-2,8-διαζαδικυκλο[4.3.0]εννεαν-8-υλ)-6-φθορο-1,4-διυδρο-4-οξο-3-κινολινο-καρβοξυλικου οξεος
WO2007017585A3 (fr) Nouveaux composes analogues de la camptothecine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EA200501164A1 (ru) Индазоламиды с аналгетической активностью
EA200300272A1 (ru) Новые производные хиназолина, способ их получения и фармацевтические композиции, содержащие их

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties